Patent · US Active

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

US11191818B2 · kind B2 · utility

0Cited by

2References

45Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Bruce Ewenstein · Brookline, US
Brahm Goldstein · Cambridge, US
Bernhard Majer · Wien, AT
Paolo ROSSATO · Marburg, DE
Friedrich Scheiflinger · Wien, AT
Marietta Turecek · Mauerbach, AT

Key dates

Filing date	Aug 4, 2017
Grant date	Dec 7, 2021
Priority date	—
Expiry date	Aug 4, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.